Ultra-long-acting insulins (IDegAsp twice daily) demonstrated a 62% reduction in overall hypoglycemia compared to BIAsp 30 twice daily (p = 0.007) in one RCT (21) and reported no severe hypoglycemic episodes in another cohort study (32). This evidence concerns the gene INS and Hypoglycemia.